ABSTRACT

Ankylosing spondylitis (AS) is the prototype of spondyloarthropathies. Non-steroid anti-inflammatory drugs are the primary treatment of choice. Sulphasalazine is especially preferred for AS patients with peripheral joint involvement. Anti-TNF agents may be selected for patients resistant to NSAID or sulphasalazine. Certolizumab pegol has been shown to be effective and safe for AS patients with spinal involvement and extraspinal findings like uveitis in phase 3, randomized and placebo controlled studies. Certolizumab pegol is an adequate choice for AS.